Home › Funds › ARMISTICE CAPITAL, LLC › NBIX

ARMISTICE CAPITAL, LLC position in NBIX

NEUROCRINE BIOSCIENCES INC · Health Care

ARMISTICE CAPITAL, LLC reported holding 535,838 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$90.3M, representing 1.19% of its reported portfolio and ranking #7 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed NBIX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)535.84K sh
Reported value held$90.31M
Portfolio Weight1.19%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ARMISTICE CAPITAL, LLC's NBIX position evolved

ARMISTICE CAPITAL, LLC first disclosed a stake in NBIX in Q3 2023 at 1,216,365 shares (US$136.8M). The position peaked in Q1 2024 at 1,023,739 shares, worth US$141.2M. Across 12 filings, ARMISTICE CAPITAL, LLC increased the stake 4 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 535,838 shares valued at US$90.3M — a reduction of -188,162 shares quarter over quarter.. Notable position changes include a 81% trim in Q3 2024 (shares rose 18% over the following quarter), a 392% increase in Q4 2024 (shares fell 19% over the following quarter), a 32% trim in Q2 2025 (shares rose 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.22M $136.84M New
Q4 2023 1.05M $138.08M Reduce
Q1 2024 1.02M $141.19M Reduce
Q2 2024 978.49K $134.71M Reduce
Q3 2024 181.38K $20.90M Reduce
Q4 2024 892.00K $121.76M Add
Q1 2025 1.00M $110.62M Add
Q2 2025 676.02K $84.97M Reduce
Q3 2025 697.02K $97.85M Add
Q4 2025 820.24K $116.33M Add
Q1 2026 724.00K $95.38M Reduce
Q2 2026 535.84K $90.31M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NBIX and 13F data

NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 34 other funds we track also report a position in NBIX — the largest reported positions include Renaissance Technologies (US$393.7M), Two Sigma Investments (US$349.9M), Vestal Point Capital, LP (US$316.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NBIX

All NBIX fund holders →

FAQ

How long has ARMISTICE CAPITAL, LLC held NBIX?

ARMISTICE CAPITAL, LLC has disclosed NBIX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ARMISTICE CAPITAL, LLC's current position in NBIX?

As of Q2 2026, ARMISTICE CAPITAL, LLC holds 535.84K shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $90.31M, representing 1.19% of its reported portfolio and ranking #7.

Has ARMISTICE CAPITAL, LLC been buying or selling NBIX?

In the latest 13F filing (Q2 2026), ARMISTICE CAPITAL, LLC reduced its position in NBIX. The position peaked in Q1 2024 at 1.02M shares.

Which other funds hold NBIX?

Other major institutional holders of NBIX include Renaissance Technologies, Two Sigma Investments, Vestal Point Capital, LP, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.